MX366912B - Producción de vacuna recombinante en e. coli mediante conjugación enzimática. - Google Patents
Producción de vacuna recombinante en e. coli mediante conjugación enzimática.Info
- Publication number
- MX366912B MX366912B MX2015005797A MX2015005797A MX366912B MX 366912 B MX366912 B MX 366912B MX 2015005797 A MX2015005797 A MX 2015005797A MX 2015005797 A MX2015005797 A MX 2015005797A MX 366912 B MX366912 B MX 366912B
- Authority
- MX
- Mexico
- Prior art keywords
- coli
- production
- recombinant vaccine
- enzymatic conjugation
- glycoconjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Una bacteria Gram-negativa diseñada para la producción de polisacárido, dicha bacteria Gram-negativa está caracterizada porque comprende (a) a un ácido nucleico que codifica un gen regular wzg, wzh, wzd o wze de ubn complejo génico de polisacárido capsular de S. pneumoniae CPS1, CPES2, CPS3, CPS4, CPS5, CPS6 (A y B) , CPS7 (A, B, C), CPS8, CPS9 (A, L, N, V, ), CPS10 (A, B, C, F,) CPS11 (A,B,C,D,F,) CPS12 (A, B,F) , CPS13, CPS14 CPS15 (A, B,C,F), CPS16 (A,F), CPS17 (A, F), CPS18 (A, B, F), CPS19 (A,B, C, F) CPS20, CPS21, CPS22 (A,F) CPS23 (A,B,F), CPS24 (A,B,F), CPS25 (A, F) CPS26, CPS27, CPS28 (A,F) CPS29, CPS31, CPS32 (A,F) CPS33 (A, B,C,D,F), CPS34, CPS35 (A, B,C,D,F,) CPS36, CPS37, CPS38, CPS39, CPS40, CPS41 (A,F)CPS42, CPS43, CPS44, CPS45, CPS46, CPS47 (A,F), o CPS48; o (b) un ácido nucleico que codifica un gen regulador capA, capB o capC de un complejo génico de polisacárido capsular de Staphylococcus auereus CPS5, o CPS8; o (c) un ácido nucleico que codifica un gen regulador CpsA, CpsB, CpsC o CpsD de un complejo génico de polisacárido capsular de Streptococcus agalactiae (grupo B, GBS) CPSIa, CPSlb, CPSII, CPSIII, CPSIV, CPSV, CPSVI, CPSVII, O CPSVIII, en donde la bacteria Gramj-negativa además comprende una oligosacaril-transferasa la cual es heterólogo para la bacteria Gram-negativa.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723408P | 2012-11-07 | 2012-11-07 | |
| PCT/EP2013/073266 WO2014072405A1 (en) | 2012-11-07 | 2013-11-07 | Production of recombinant vaccine in e. coli by enzymatic conjugation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015005797A MX2015005797A (es) | 2016-03-09 |
| MX366912B true MX366912B (es) | 2019-07-30 |
Family
ID=49552366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015005797A MX366912B (es) | 2012-11-07 | 2013-11-07 | Producción de vacuna recombinante en e. coli mediante conjugación enzimática. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20150273043A1 (es) |
| EP (3) | EP2917351B1 (es) |
| JP (2) | JP6412875B2 (es) |
| KR (1) | KR20150079964A (es) |
| CN (1) | CN105008539B (es) |
| AU (2) | AU2013343520B2 (es) |
| BR (1) | BR112015010283A8 (es) |
| CA (2) | CA3125293A1 (es) |
| EA (1) | EA201590705A1 (es) |
| ES (3) | ES2713166T3 (es) |
| IL (1) | IL238586A0 (es) |
| MX (1) | MX366912B (es) |
| SG (1) | SG11201503308XA (es) |
| TR (1) | TR201903066T4 (es) |
| WO (1) | WO2014072405A1 (es) |
| ZA (1) | ZA201503097B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2501406T3 (pl) * | 2009-11-19 | 2018-05-30 | Glaxosmithkline Biologicals S.A. | Biosyntetyczny układ wytwarzający immunogenne polisacharydy w komórkach prokariotycznych |
| EA201690529A1 (ru) * | 2013-10-11 | 2016-11-30 | Гликоваксин Аг | Способы модификации клетки-хозяина |
| WO2015158403A1 (en) * | 2014-04-17 | 2015-10-22 | Glycovaxyn Ag | Modified host cells and uses thereof |
| JP6666901B2 (ja) | 2014-08-08 | 2020-03-18 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | バイオコンジュゲート生成において使用するための改変型宿主細胞 |
| AU2016224006B8 (en) * | 2015-02-26 | 2020-03-19 | Vaxnewmo Llc | Acinetobacter O-oligosaccharyltransferases and uses thereof |
| GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
| GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
| CN105963691B (zh) * | 2016-07-03 | 2020-05-01 | 查文娟 | 一种肺炎链球菌疫苗 |
| CN106929573B (zh) * | 2017-02-21 | 2020-06-09 | 南开大学 | 对嗜肺军团菌O12型的wzm和wecA基因特异的核苷酸序列及其应用 |
| GB201712678D0 (en) * | 2017-08-07 | 2017-09-20 | Glaxosmithkline Biologicals Sa | Process for the manipulation of nucleic acids |
| WO2019043245A1 (en) * | 2017-09-04 | 2019-03-07 | London School Of Hygiene And Tropical Medicine | MICROBIAL CELLS EXPRESSING STREPTOCOCCAL SERROTYPES |
| US11235046B2 (en) | 2017-11-04 | 2022-02-01 | Nevada Research & Innovation Corporation | Immunogenic conjugates and methods of use thereof |
| GB201721582D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
| GB201721576D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
| US11932670B2 (en) | 2018-06-16 | 2024-03-19 | Vaxnewmo Llc | Glycosylated ComP pilin variants, methods of making and uses thereof |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| EP3650044A1 (en) * | 2018-11-06 | 2020-05-13 | ETH Zürich | Anti-glycan vaccines |
| EP4253554A3 (en) * | 2019-03-18 | 2024-01-17 | Janssen Pharmaceuticals, Inc. | Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof |
| EP3770269A1 (en) | 2019-07-23 | 2021-01-27 | GlaxoSmithKline Biologicals S.A. | Quantification of bioconjugate glycosylation |
| CN111518738B (zh) * | 2020-05-08 | 2022-02-08 | 徐州海润生物科技有限公司 | 重组卡介苗及其制备方法和应用 |
| WO2021259743A2 (en) | 2020-06-25 | 2021-12-30 | Glaxosmithkline Biologicals Sa | Vaccine |
| WO2023118033A1 (en) | 2021-12-22 | 2023-06-29 | Glaxosmithkline Biologicals Sa | Vaccine |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2638595A (en) * | 1994-05-16 | 1995-12-05 | Uab Research Foundation, The | (streptococcus pneumoniae) capsular polysaccharide genes and flanking regions |
| US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
| US7541043B2 (en) | 2002-01-16 | 2009-06-02 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine for protection against Shigella sonnei disease |
| DE60303591T2 (de) | 2002-03-07 | 2007-03-01 | Eidgenössische Technische Hochschule Zürich | System und methode zur herstellung von rekombinanten, glykosylierten protein in prokaryontischen wirtszellen |
| EP1888761B1 (en) | 2005-05-11 | 2010-09-29 | ETH Zurich | Recombinant n-glycosylated proteins from procaryotic cells |
| DK2257307T3 (en) | 2008-02-20 | 2018-08-20 | Glaxosmithkline Biologicals Sa | BIOCONJUGATES MANUFACTURED FROM RECOMBINANT N-Glycosylated PROTEINS FROM PROCARYOTIC CELLS |
| US9358302B2 (en) * | 2009-03-23 | 2016-06-07 | The Brigham And Women's Hospital, Inc. | Glycoconjugate vaccines |
| KR20120085240A (ko) | 2009-07-17 | 2012-07-31 | 오션 하베스트 테크놀로지 (캐나다) 아이엔씨. | 어류 사료에서 합성 첨가제를 대체하는 천연 및 지속 가능 해조류 배합 |
| JP6339366B2 (ja) | 2010-05-06 | 2018-06-06 | グリコヴァキシン アーゲー | 莢膜グラム陽性菌のバイオコンジュゲートワクチン |
| CA2887133C (en) * | 2012-10-12 | 2022-05-03 | Glycovaxyn Ag | Methods of host cell modification |
-
2013
- 2013-11-07 KR KR1020157014830A patent/KR20150079964A/ko not_active Application Discontinuation
- 2013-11-07 EP EP13788753.5A patent/EP2917351B1/en active Active
- 2013-11-07 TR TR2019/03066T patent/TR201903066T4/tr unknown
- 2013-11-07 ES ES13788753T patent/ES2713166T3/es active Active
- 2013-11-07 SG SG11201503308XA patent/SG11201503308XA/en unknown
- 2013-11-07 ES ES18198665T patent/ES2848774T3/es active Active
- 2013-11-07 CA CA3125293A patent/CA3125293A1/en active Pending
- 2013-11-07 EA EA201590705A patent/EA201590705A1/ru unknown
- 2013-11-07 US US14/440,311 patent/US20150273043A1/en not_active Abandoned
- 2013-11-07 EP EP18198665.4A patent/EP3444352B1/en active Active
- 2013-11-07 CA CA2889767A patent/CA2889767C/en active Active
- 2013-11-07 AU AU2013343520A patent/AU2013343520B2/en active Active
- 2013-11-07 BR BR112015010283A patent/BR112015010283A8/pt not_active Application Discontinuation
- 2013-11-07 JP JP2015541130A patent/JP6412875B2/ja active Active
- 2013-11-07 CN CN201380069524.XA patent/CN105008539B/zh active Active
- 2013-11-07 EP EP18211761.4A patent/EP3508579B1/en active Active
- 2013-11-07 MX MX2015005797A patent/MX366912B/es active IP Right Grant
- 2013-11-07 WO PCT/EP2013/073266 patent/WO2014072405A1/en active Application Filing
- 2013-11-07 ES ES18211761T patent/ES2882282T3/es active Active
-
2015
- 2015-05-03 IL IL238586A patent/IL238586A0/en unknown
- 2015-05-06 ZA ZA2015/03097A patent/ZA201503097B/en unknown
-
2017
- 2017-12-20 AU AU2017279688A patent/AU2017279688B2/en active Active
-
2018
- 2018-07-13 US US16/034,906 patent/US10973901B2/en active Active
- 2018-10-01 JP JP2018186302A patent/JP6833785B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015005797A (es) | Produccion de vacuna recombinante en e.coli mediante conjugacion enzimatica. | |
| ZA201601534B (en) | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses | |
| MX2019010441A (es) | Composiciones y metodos. | |
| SG10201900948PA (en) | Modified nucleotide linkers | |
| MX2015008027A (es) | Proceso de glicoconjugacion. | |
| MY191370A (en) | Production of odd chain fatty acid derivatives in recombinant microbial cells | |
| MX2018014043A (es) | Composiciones de cultivo celular con antioxidantes y metodos para la produccion de polipeptidos. | |
| MX2013009175A (es) | Composiciones que comprenden acido peroxi alfa-cetocarboxilico y metodos para producirlas y usarlas. | |
| MX2013004353A (es) | Produccion recombinante de n-propanol e isopropanol. | |
| MX351565B (es) | Colageno 7 y metodos relacionados. | |
| WO2012068317A3 (en) | Methods for producing recombinant proteins | |
| IN2014DN06104A (es) | ||
| IN2012DN02210A (es) | ||
| MY182946A (en) | Production of organic acids by fermentation at low ph | |
| MX2020001357A (es) | Produccion microbiana de aminas grasas. | |
| IN2015DN03206A (es) | ||
| MX2011012623A (es) | Construcciones de casb7439. | |
| IN2012DN02760A (es) | ||
| MX2014010958A (es) | Composicion de celulas inmunoestimuladora activada y sus usos. | |
| MX2014007760A (es) | Bacterias con unidades transcripcionales reconstruidas y los usos de las mismas. | |
| MX2012007283A (es) | Composiciones para vacunas. | |
| WO2015117033A3 (en) | Methods of increasing protein production in mammalian cells | |
| GB2528604A (en) | Modulation of asymmetric proliferation | |
| MX2013005749A (es) | Composiciones y metodos para producir enterocinasa en levaduras. | |
| RU2010119250A (ru) | Штамм bifidobacterium adolescentis рвв-1, используемый для получения продукции |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A. |
|
| FG | Grant or registration |